PACIRA BIOSCIENCES, INC. Current Federal Tax Expense (Benefit)
PACIRA BIOSCIENCES, INC. (PCRX) reported Current Federal Tax Expense (Benefit) of $1.85 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for the quarter ending 2020-12-31 was -$6.00K.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for the quarter ending 2020-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for the quarter ending 2019-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for the quarter ending 2019-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for fiscal 2025 was $1.85M, a 80.04% decline from fiscal 2024.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for fiscal 2024 was $9.29M, a 451.30% increase from fiscal 2023.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for fiscal 2023 was $1.69M.
- PACIRA BIOSCIENCES, INC. current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 6 month | Current Federal Tax Expense (Benefit) 9 month | Current Federal Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.85M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $9.29M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $1.69M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2020-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$6.00K derived: sum of 2 quarters · filed 2023-02-28 | -$6.00K 10-K · filed 2023-02-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-30 | $0.00 10-Q · filed 2020-10-30 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-30 | $0.00 10-Q · filed 2020-10-30 | ||
| 2018-12-31 | -$96.00K 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-21 | |||
| 2016-12-31 | $11.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $92.00K 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | $0.00 10-K · filed 2016-02-25 | ||
| 2013-12-31 | $0.00 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |